Effects of Sclerostin Antibody on Bone Healing

Overview

Journal World J Orthop

Publisher Baishideng Publishing Group

Specialty Orthopedics

Date 2021 Oct 11

PMID 34631449

Citations 4

Authors

Atsushi Mihara

Kiminori Yukata

Toshihiro Seki

Ryuta Iwanaga

Norihiro Nishida

Kenzo Fujii

Yuji Nagao

Takashi Sakai

Affiliations

Soon will be listed here.

Abstract

Promoting bone healing after a fracture has been a frequent subject of research. Recently, sclerostin antibody (Scl-Ab) has been introduced as a new anabolic agent for the treatment of osteoporosis. Scl-Ab activates the canonical Wnt (cWnt)-β-catenin pathway, leading to an increase in bone formation and decrease in bone resorption. Because of its rich osteogenic effects, preclinically, Scl-Ab has shown positive effects on bone healing in rodent models; researchers have reported an increase in bone mass, mechanical strength, histological bone formation, total mineralized callus volume, bone mineral density, neovascularization, proliferating cell nuclear antigen score, and bone morphogenic protein expression at the fracture site after Scl-Ab administration. In addition, in a rat critical-size femoral-defect model, the Scl-Ab-treated group demonstrated a higher bone healing rate. On the other hand, two clinical reports have researched Scl-Ab in bone healing and failed to show positive effects in the femur and tibia. This review discusses why Scl-Ab appears to be effective in animal models of fracture healing and not in clinical cases.

Citing Articles

Close negative correlation of local and circulating Dickkopf-1 and Sclerostin levels during human fracture healing.

Starlinger J, Santol J, Kaiser G, Sarahrudi K Sci Rep. 2024; 14(1):6524.

PMID: 38499638 PMC: 10948769. DOI: 10.1038/s41598-024-55756-5.

Fracture healing-orthobiologics: from basic science to clinical application.

Johnson J, Ahn J, Dirschl D, Wixted J, Evans A OTA Int. 2023; 6(2 Suppl):e262.

PMID: 37168028 PMC: 10166332. DOI: 10.1097/OI9.0000000000000262.

Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis.

Diaconu A, Ceasovschih A, Sorodoc V, Pomirleanu C, Lionte C, Sorodoc L Int J Mol Sci. 2022; 23(19).

PMID: 36232862 PMC: 9570274. DOI: 10.3390/ijms231911561.

Gingival Mesenchymal Stem Cells Metabolite Decreasing TRAP, NFATc1, and Sclerostin Expression in LPS-Associated Inflammatory Osteolysis In Vivo.

Nugraha A, Ramadhani N, Riawan W, Ihsan I, Ernawati D, Ridwan R Eur J Dent. 2022; 17(3):881-888.

PMID: 35728613 PMC: 10569879. DOI: 10.1055/s-0042-1748529.

References

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

Marsell R, Einhorn T . The biology of fracture healing. Injury. 2011; 42(6):551-5. PMC: 3105171. DOI: 10.1016/j.injury.2011.03.031. View

Wise J, Sena K, Vranizan K, Pollock J, Healy K, Hughes W . Temporal gene expression profiling during rat femoral marrow ablation-induced intramembranous bone regeneration. PLoS One. 2010; 5(10). PMC: 2948496. DOI: 10.1371/journal.pone.0012987. View

Agholme F, Li X, Isaksson H, Ke H, Aspenberg P . Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010; 25(11):2412-8. DOI: 10.1002/jbmr.135. View

VAN BUCHEM F, HADDERS H, UBBENS R . An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol (Stockh). 1955; 44(2):109-20. View

Virk M, Alaee F, Tang H, Ominsky M, Ke H, Lieberman J . Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am. 2013; 95(8):694-701. PMC: 3748979. DOI: 10.2106/JBJS.L.00285. View

Yukata K, Xie C, Li T, Takahata M, Hoak D, Kondabolu S . Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment. Bone. 2014; 62:79-89. PMC: 4085793. DOI: 10.1016/j.bone.2014.02.002. View

Langdahl B, Libanati C, Crittenden D, Bolognese M, Brown J, Daizadeh N . Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102):1585-1594. DOI: 10.1016/S0140-6736(17)31613-6. View

Lim S, Bolster M . Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther. 2017; 11:1221-1231. PMC: 5402913. DOI: 10.2147/DDDT.S127568. View

10.

Wergedal J, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C . Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab. 2003; 88(12):5778-83. DOI: 10.1210/jc.2003-030201. View

11.

Alzahrani M, Rauch F, Hamdy R . Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?. Clin Orthop Relat Res. 2015; 474(5):1294-302. PMC: 4814400. DOI: 10.1007/s11999-015-4640-z. View

12.

Kruck B, Zimmermann E, Damerow S, Figge C, Julien C, Wulsten D . Sclerostin Neutralizing Antibody Treatment Enhances Bone Formation but Does Not Rescue Mechanically Induced Delayed Healing. J Bone Miner Res. 2018; 33(9):1686-1697. DOI: 10.1002/jbmr.3454. View

13.

Bhandari M, Schemitsch E, Karachalios T, Sancheti P, Poolman R, Caminis J . Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study. J Bone Joint Surg Am. 2020; 102(16):1416-1426. DOI: 10.2106/JBJS.19.01008. View

14.

Montjovent M, Siegrist M, Klenke F, Wetterwald A, Dolder S, Hofstetter W . Expression of antagonists of WNT and BMP signaling after non-rigid fixation of osteotomies. Bone. 2012; 53(1):79-86. DOI: 10.1016/j.bone.2012.11.027. View

15.

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F . Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011; 286(22):19489-500. PMC: 3103328. DOI: 10.1074/jbc.M110.190330. View

16.

van Lierop A, Hamdy N, van Egmond M, Bakker E, Dikkers F, Papapoulos S . Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2012; 28(4):848-54. DOI: 10.1002/jbmr.1794. View

17.

Rhee Y, Allen M, Condon K, Lezcano V, Ronda A, Galli C . PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 2010; 26(5):1035-46. PMC: 3179307. DOI: 10.1002/jbmr.304. View

18.

Brunkow M, Gardner J, Van Ness J, Paeper B, Kovacevich B, Proll S . Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68(3):577-89. PMC: 1274471. DOI: 10.1086/318811. View

19.

Li X, Ominsky M, Niu Q, Sun N, Daugherty B, DAgostin D . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):860-9. DOI: 10.1359/jbmr.080216. View

20.

Suen P, He Y, Chow D, Huang L, Li C, Ke H . Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats. J Orthop Res. 2014; 32(8):997-1005. DOI: 10.1002/jor.22636. View